Oncology Nurse Edition Editorial and Publishing Staff April 2011

Article

EDITORIAL AND PUBLISHING STAFF

Cindy FlaumVP, Clinical Publishing

Rachel WarrenEditorial Director

Anne LandryExecutive Editor

Nancy BittekerDirector, Design & Digital Production

Meg StrizverProduction Manager

Amy Birnbach
Group Publisher, Oncology

Sarah MifsudDigital Sales

William Markowitz, RPhPublishing Director

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
2 experts in this video
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
2 experts in this video
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content